1-3 of 3
David M Goldenberg, Sc.D., M.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Epratuzumab (Humanized Anti-CD22 MAb) Conjugated with SN-38, a New Antibody-Drug Conjugate (ADC) for the Treatment of Hematologic Tumors: Preclinical Studies Alone and In Combination with Veltuzumab, a Humanized Anti-CD20 MAb

David M Goldenberg, Sc.D., M.D., Serengulam Govindan, Ph.D., Tom M Cardillo, Ph.D., Robert M Sharkey, Ph.D.
Journal: Blood
Blood (2010) 116 (21): 3941.
https://doi.org/10.1182/blood.V116.21.3941.3941
Published: 2010
Journal Articles

Milatuzumab Improves Efficacy of Current Treatments for B-Cell Malignancies.

Rhona Stein, Ph.D., Susan Chen, Francisco J. Hernandez-Ilizaliturri, M.D., Myron S. Czuczman, MD, David M. Goldenberg, Sc.D., M.D.
Journal: Blood
Blood (2010) 116 (21): 2837.
https://doi.org/10.1182/blood.V116.21.2837.2837
Published: 2010
Journal Articles

Multivalent Anti-CD20/Anti-CD22 Bispecific Antibody Fusion Proteins Made by the DNL Method Show Potent Lymphoma Cytotoxicity.

Edmund A. Rossi, PhD, Michele J. Losman, Ph.D., Diane L. Nordstrom, M.S., Thomas Cardillo, Ph.D., Meiyu Loo, M.S., John Kopinski, B.S., Zhengxing Qu, Ph.D., David M. Goldenberg, Sc.D., M.D., Chien-Hsing Chang, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 2495.
https://doi.org/10.1182/blood.V108.11.2495.2495
Published: 2006